{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T15:47:16Z","timestamp":1774021636812,"version":"3.50.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Complement Med Ther"],"DOI":"10.1186\/s12906-026-05279-5","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T07:34:32Z","timestamp":1770968072000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Exploring the underlying mechanisms of Hedyotis diffusa and Scutellaria Barbata herb pair on the prognosis and treatment efficacy of bladder cancer patients: an integrated approach of network pharmacology and bioinformatics analysis"],"prefix":"10.1186","volume":"26","author":[{"given":"Yuan","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liyuan","family":"Duan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengwei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenzhen","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yonghao","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuepei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhaowei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,13]]},"reference":[{"issue":"7","key":"5279_CR1","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1097\/CM9.0000000000001474","volume":"134","author":"W Cao","year":"2021","unstructured":"Cao W, Chen H-D, Yu Y-W, Li N, Chen W-Q. Changing profiles of cancer burden worldwide and in china: a secondary analysis of the global cancer statistics 2020. Chin Med J. 2021;134(7):783\u201391.","journal-title":"Chin Med J"},{"issue":"1","key":"5279_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.eururo.2023.08.016","volume":"85","author":"J Alfred Witjes","year":"2024","unstructured":"Alfred Witjes J, Max Bruins H, Carri\u00f3n A, Cathomas R, Comp\u00e9rat E, Efstathiou JA, Fietkau R, Gakis G, Lorch A, Martini A, et al. European association of urology guidelines on Muscle-invasive and metastatic bladder cancer: summary of the 2023 guidelines. Eur Urol. 2024;85(1):17\u201331.","journal-title":"Eur Urol"},{"issue":"1","key":"5279_CR3","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","volume":"81","author":"M Babjuk","year":"2022","unstructured":"Babjuk M, Burger M, Capoun O, Cohen D, Comp\u00e9rat EM, Dominguez Escrig JL, Gontero P, Liedberg F, Masson-Lecomte A, Mostafid AH, et al. European association of urology guidelines on Non\u2013muscle-invasive bladder cancer (Ta, T1, and carcinoma in Situ). Eur Urol. 2022;81(1):75\u201394.","journal-title":"Eur Urol"},{"issue":"3","key":"5279_CR4","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"Cancer J Clin"},{"key":"5279_CR5","doi-asserted-by":"crossref","unstructured":"Zhang Y, Rumgay H, Li M, Yu H, Pan H, Ni J. The global landscape of bladder cancer incidence and mortality in 2020 and projections to 2040. J Global Health, 13:04109.","DOI":"10.7189\/jogh.13.04109"},{"issue":"2","key":"5279_CR6","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.eururo.2013.06.049","volume":"65","author":"F Petrelli","year":"2014","unstructured":"Petrelli F, Coinu A, Cabiddu M, Ghilardi M, Vavassori I, Barni S. Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy: A Meta-analysis. Eur Urol. 2014;65(2):350\u20137.","journal-title":"Eur Urol"},{"issue":"4","key":"5279_CR7","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1097\/JU.0000000000001855","volume":"206","author":"NH Chakiryan","year":"2021","unstructured":"Chakiryan NH, Jiang DD, Gillis KA, Green E, Hajiran A, Hugar L, Zemp L, Zhang J, Jain R, Chahoud J et al. Pathological downstaging and survival outcomes associated with Neoadju Vant chemotherapy for variant histology muscle invasive bladder cancer. J Urol, 206(4):924\u201332.","journal-title":"J Urol"},{"issue":"1","key":"5279_CR8","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.eururo.2021.09.028","volume":"81","author":"S Burdett","year":"2022","unstructured":"Burdett S, Fisher DJ, Vale CL, Sternberg CN, Clarke NW, Parmar MKB, Bono AV, Cognetti F, Collette L, Cote RJ, et al. Adjuvant chemotherapy for Muscle-invasive bladder cancer: A systematic review and Meta-analysis of individual participant data from randomised controlled trials. Eur Urol. 2022;81(1):50\u201361.","journal-title":"Eur Urol"},{"key":"5279_CR9","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.jep.2018.02.020","volume":"217","author":"Q Wang","year":"2018","unstructured":"Wang Q, Acharya N, Liu Z, Zhou X, Cromie M, Zhu J, Gao W. Enhanced anticancer effects of scutellaria Barbata D. Don in combination with traditional Chinese medicine components on non-small cell lung cancer cells. J Ethnopharmacol. 2018;217:140\u201351.","journal-title":"J Ethnopharmacol"},{"issue":"3","key":"5279_CR10","doi-asserted-by":"publisher","first-page":"220","DOI":"10.5582\/bst.2018.01144","volume":"12","author":"Z Wang","year":"2018","unstructured":"Wang Z, Qi F, Cui Y, Zhao L, Sun X, Tang W, Cai P. An update on Chinese herbal medicines as adjuvant treatment of anticancer therapeutics. Biosci Trends. 2018;12(3):220\u201339.","journal-title":"Biosci Trends"},{"key":"5279_CR11","doi-asserted-by":"publisher","first-page":"112929","DOI":"10.1016\/j.jep.2020.112929","volume":"259","author":"TT Ma","year":"2020","unstructured":"Ma TT, Zhang GL, Dai CF, Zhang BR, Cao KX, Wang CG, Yang GW, Wang XM. Scutellaria Barbata and Hedyotis diffusa herb pair for breast cancer treatment: potential mechanism based on network Pharmacology. J Ethnopharmacol. 2020;259:112929.","journal-title":"J Ethnopharmacol"},{"key":"5279_CR12","doi-asserted-by":"publisher","first-page":"114343","DOI":"10.1016\/j.jep.2021.114343","volume":"279","author":"X Xu","year":"2021","unstructured":"Xu X, Chen F, Zhang L, Liu L, Zhang C, Zhang Z, Li W. Exploring the mechanisms of anti-ovarian cancer of Hedyotis diffusa willd and scutellaria Barbata D. Don through focal adhesion pathway. J Ethnopharmacol. 2021;279:114343.","journal-title":"J Ethnopharmacol"},{"key":"5279_CR13","doi-asserted-by":"publisher","first-page":"106916","DOI":"10.1016\/j.fitote.2025.106916","volume":"187","author":"Y Mi","year":"2025","unstructured":"Mi Y, Tian X, Yang Q, Wang B. Hedyotis diffusa Willd.-Scutellaria Barbata D.Don herb pair induces ferroptosis in gastric cancer by inhibiting the PI3K\/AKT\/HIF-1\u03b1 pathway. Fitoterapia. 2025;187:106916.","journal-title":"Fitoterapia"},{"key":"5279_CR14","doi-asserted-by":"publisher","first-page":"157634","DOI":"10.1016\/j.phymed.2025.157634","volume":"150","author":"J Chen","year":"2025","unstructured":"Chen J, Li R, He Z, Nie Y, Lu L, Xin W, Liu X, Xu H. Hedyotis diffusa willd-scutellaria Barbata herbal pair ameliorates colitis-associated colorectal cancer progression by modulating the gut microbiota and the PPAR\u03b3\/NF-\u03baB pathway. Phytomedicine. 2025;150:157634.","journal-title":"Phytomedicine"},{"key":"5279_CR15","doi-asserted-by":"crossref","unstructured":"Wang Y, Yang H, Chen L, Jafari M, Tang J. Network-based modeling of herb combinations in traditional Chinese medicine. Brief Bioinform 2021, 22(5):1-13.","DOI":"10.1093\/bib\/bbab106"},{"issue":"1","key":"5279_CR16","doi-asserted-by":"publisher","first-page":"9174903","DOI":"10.1155\/2016\/9174903","volume":"2016","author":"L-T Pan","year":"2016","unstructured":"Pan L-T, Sheung Y, Guo W-P, Rong Z-B, Cai Z-M. Hedyotis diffusa plus scutellaria Barbata induce bladder cancer cell apoptosis by inhibiting Akt signaling pathway through downregulating miR-155 expression. Evidence-Based Complement Altern Med. 2016;2016(1):9174903.","journal-title":"Evidence-Based Complement Altern Med"},{"issue":"1","key":"5279_CR17","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s12943-024-02095-8","volume":"23","author":"Q Liu","year":"2024","unstructured":"Liu Q, Guan Y, Li S. Programmed death receptor (PD-)1\/PD-ligand (L)1 in urological cancers: the all-around warrior in immunotherapy. Mol Cancer. 2024;23(1):183.","journal-title":"Mol Cancer"},{"issue":"12","key":"5279_CR18","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1002\/ijc.33794","volume":"149","author":"H Lai","year":"2021","unstructured":"Lai H, Cheng X, Liu Q, Luo W, Liu M, Zhang M, Miao J, Ji Z, Lin GN, Song W, et al. Single-cell RNA sequencing reveals the epithelial cell heterogeneity and invasive subpopulation in human bladder cancer. Int J Cancer. 2021;149(12):2099\u2013115.","journal-title":"Int J Cancer"},{"key":"5279_CR19","doi-asserted-by":"publisher","first-page":"110820","DOI":"10.1016\/j.biopha.2020.110820","volume":"132","author":"Y Fan","year":"2020","unstructured":"Fan Y, Ma Z, Zhao L, Wang W, Gao M, Jia X, Ouyang H, He J. Anti-tumor activities and mechanisms of traditional Chinese medicines formulas: A review. Biomed Pharmacother. 2020;132:110820.","journal-title":"Biomed Pharmacother"},{"issue":"01","key":"5279_CR20","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1142\/S0192415X2450006X","volume":"52","author":"J Fu","year":"2024","unstructured":"Fu J, Xie X, Yao H, Xiao H, Li Z, Wang Z, Ju R, Zhao Y, Liu Z, Zhang N. The effectiveness of traditional Chinese medicine in treating malignancies via regulatory cell death pathways and the tumor immune microenvironment: A review of recent advances. Am J Chin Med. 2024;52(01):137\u201360.","journal-title":"Am J Chin Med"},{"issue":"2","key":"5279_CR21","doi-asserted-by":"publisher","first-page":"e08994","DOI":"10.1016\/j.heliyon.2022.e08994","volume":"8","author":"X Li","year":"2022","unstructured":"Li X, Yang L, Huang W, Jia B, Lai Y. Immunological significance of alternative splicing prognostic signatures for bladder cancer. Heliyon. 2022;8(2):e08994.","journal-title":"Heliyon"},{"key":"5279_CR22","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ebiom.2018.03.034","volume":"31","author":"S-X Wu","year":"2018","unstructured":"Wu S-X, Huang J, Liu Z-W, Chen H-G, Guo P, Cai Q-Q, Zheng J-J, Qin H-D, Zheng Z-S, Chen X, et al. A Genomic-clinicopathologic nomogram for the preoperative prediction of lymph node metastasis in bladder cancer. EBioMedicine. 2018;31:54\u201365.","journal-title":"EBioMedicine"},{"key":"5279_CR23","doi-asserted-by":"publisher","first-page":"119035","DOI":"10.1016\/j.jep.2024.119035","volume":"338","author":"J Li","year":"2025","unstructured":"Li J, Fan S, Li H, Hu Z, Hu Q. Evaluation of efficacy, safety and underlying mechanism on traditional Chinese medicine as synergistic agents for cancer immunotherapy: A preclinical systematic review and meta-analysis. J Ethnopharmacol. 2025;338:119035.","journal-title":"J Ethnopharmacol"},{"issue":"3","key":"5279_CR24","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","volume":"41","author":"KE de Visser","year":"2023","unstructured":"de Visser KE, Joyce JA. The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth. Cancer Cell. 2023;41(3):374\u2013403.","journal-title":"Cancer Cell"},{"issue":"1","key":"5279_CR25","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/s41467-017-02424-0","volume":"9","author":"M Efremova","year":"2018","unstructured":"Efremova M, Rieder D, Klepsch V, Charoentong P, Finotello F, Hackl H, Hermann-Kleiter N, L\u00f6wer M, Baier G, Krogsdam A, et al. Targeting immune checkpoints potentiates immunoediting and changes the dynamics of tumor evolution. Nat Commun. 2018;9(1):32.","journal-title":"Nat Commun"},{"key":"5279_CR26","doi-asserted-by":"publisher","first-page":"100718","DOI":"10.1016\/j.drup.2020.100718","volume":"53","author":"E P\u00e9rez-Ruiz","year":"2020","unstructured":"P\u00e9rez-Ruiz E, Melero I, Kopecka J, Sarmento-Ribeiro AB, Garc\u00eda-Aranda M, De Las Rivas J. Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies. Drug Resist Updates. 2020;53:100718.","journal-title":"Drug Resist Updates"},{"issue":"1","key":"5279_CR27","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41577-019-0218-4","volume":"20","author":"A Kalbasi","year":"2020","unstructured":"Kalbasi A, Ribas A. Tumour-intrinsic resistance to immune checkpoint Blockade. Nat Rev Immunol. 2020;20(1):25\u201339.","journal-title":"Nat Rev Immunol"},{"issue":"9","key":"5279_CR28","doi-asserted-by":"publisher","first-page":"107722","DOI":"10.1016\/j.isci.2023.107722","volume":"26","author":"Y Qin","year":"2023","unstructured":"Qin Y, Zu X, Li Y, Han Y, Tan J, Cai C, Shen E, Liu P, Deng G, Feng Z, et al. A cancer-associated fibroblast subtypes-based signature enables the evaluation of immunotherapy response and prognosis in bladder cancer. iScience. 2023;26(9):107722.","journal-title":"iScience"},{"issue":"1","key":"5279_CR29","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1186\/s12967-024-05186-8","volume":"22","author":"K Zheng","year":"2024","unstructured":"Zheng K, Hai Y, Chen H, Zhang Y, Hu X, Ni K. Tumor immune dysfunction and exclusion subtypes in bladder cancer and pan-cancer: a novel molecular subtyping strategy and immunotherapeutic prediction model. J Translational Med. 2024;22(1):365.","journal-title":"J Translational Med"},{"issue":"10031","key":"5279_CR30","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","volume":"387","author":"JE Rosenberg","year":"2016","unstructured":"Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, Dawson N, O\u2019Donnell PH, Balmanoukian A, Loriot Y, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387(10031):1909\u201320.","journal-title":"Lancet"},{"issue":"10064","key":"5279_CR31","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","volume":"389","author":"AV Balar","year":"2017","unstructured":"Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, Loriot Y, Necchi A, Hoffman-Censits J, Perez-Gracia JL, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2017;389(10064):67\u201376.","journal-title":"Lancet"},{"issue":"12","key":"5279_CR32","doi-asserted-by":"publisher","first-page":"103972","DOI":"10.1016\/j.esmoop.2024.103972","volume":"9","author":"JE Rosenberg","year":"2024","unstructured":"Rosenberg JE, Galsky MD, Powles T, Petrylak DP, Bellmunt J, Loriot Y, Necchi A, Hoffman-Censits J, Perez-Gracia JL, van der Heijden MS, et al. Atezolizumab monotherapy for metastatic urothelial carcinoma: final analysis from the phase II IMvigor210 trial. ESMO Open. 2024;9(12):103972.","journal-title":"ESMO Open"},{"issue":"1","key":"5279_CR33","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1758-2946-6-13","volume":"6","author":"J Ru","year":"2014","unstructured":"Ru J, Li P, Wang J, Zhou W, Li B, Huang C, Li P, Guo Z, Tao W, Yang Y, et al. TCMSP: a database of systems Pharmacology for drug discovery from herbal medicines. J Cheminform. 2014;6(1):13.","journal-title":"J Cheminform"},{"issue":"1","key":"5279_CR34","doi-asserted-by":"publisher","first-page":"2130583","DOI":"10.1080\/2162402X.2022.2130583","volume":"11","author":"S Liu","year":"2022","unstructured":"Liu S, Qin Z, Mao Y, Zhang W, Wang Y, Jia L, Peng X. Therapeutic targeting of MYC in head and neck squamous cell carcinoma. OncoImmunology. 2022;11(1):2130583.","journal-title":"OncoImmunology"},{"issue":"5","key":"5279_CR35","doi-asserted-by":"publisher","first-page":"e1581529","DOI":"10.1080\/2162402X.2019.1581529","volume":"8","author":"P Pan","year":"2019","unstructured":"Pan P, Fei Y, Xiong Q, Yang J, Zhang Z, Lin X, Pan M, Lu F, Huang H. Synergistic Inhibition of pancreatic cancer with anti-PD-L1 and c-Myc inhibitor JQ1. OncoImmunology. 2019;8(5):e1581529.","journal-title":"OncoImmunology"},{"issue":"17","key":"5279_CR36","doi-asserted-by":"publisher","first-page":"4411","DOI":"10.3390\/cancers13174411","volume":"13","author":"G Roviello","year":"2021","unstructured":"Roviello G, Catalano M, Santi R, Palmieri VE, Vannini G, Galli IC, Buttitta E, Villari D, Rossi V, Nesi G. Immune checkpoint inhibitors in urothelial bladder cancer: state of the Art and future perspectives. Cancers. 2021;13(17):4411.","journal-title":"Cancers"},{"issue":"4","key":"5279_CR37","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1007\/s11427-020-1768-y","volume":"64","author":"Z Wu","year":"2021","unstructured":"Wu Z, Liu J, Dai R, Wu S. Current status and future perspectives of immunotherapy in bladder cancer treatment. Sci China Life Sci. 2021;64(4):512\u201333.","journal-title":"Sci China Life Sci"},{"issue":"3","key":"5279_CR38","doi-asserted-by":"publisher","first-page":"e694","DOI":"10.1002\/ctm2.694","volume":"12","author":"D Jovic","year":"2022","unstructured":"Jovic D, Liang X, Zeng H, Lin L, Xu F, Luo Y. Single-cell RNA sequencing technologies and applications: A brief overview. Clin Translational Med. 2022;12(3):e694.","journal-title":"Clin Translational Med"},{"issue":"6","key":"5279_CR39","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1038\/s41573-023-00688-4","volume":"22","author":"B Van de Sande","year":"2023","unstructured":"Van de Sande B, Lee JS, Mutasa-Gottgens E, Naughton B, Bacon W, Manning J, Wang Y, Pollard J, Mendez M, Hill J, et al. Applications of single-cell RNA sequencing in drug discovery and development. Nat Rev Drug Discovery. 2023;22(6):496\u2013520.","journal-title":"Nat Rev Drug Discovery"},{"issue":"4","key":"5279_CR40","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1111\/cas.14334","volume":"111","author":"K Iida","year":"2020","unstructured":"Iida K, Naiki T, Naiki-Ito A, Suzuki S, Kato H, Nozaki S, Nagai T, Etani T, Nagayasu Y, Ando R, et al. Luteolin suppresses bladder cancer growth via regulation of mechanistic target of Rapamycin pathway. Cancer Sci. 2020;111(4):1165\u201379.","journal-title":"Cancer Sci"},{"issue":"6","key":"5279_CR41","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S0090-4295(00)00467-2","volume":"55","author":"S Ikemoto","year":"2000","unstructured":"Ikemoto S, Sugimura K, Yoshida N, Yasumoto R, Wada S, Yamamoto K, Kishimoto T. Antitumor effects of scutellariae radix and its components baicalein, baicalin, and Wogonin on bladder cancer cell lines. Urology. 2000;55(6):951\u20135.","journal-title":"Urology"},{"issue":"2","key":"5279_CR42","first-page":"498","volume":"6","author":"Q Su","year":"2016","unstructured":"Su Q, Peng M, Zhang Y, Xu W, Darko KO, Tao T, Huang Y, Tao X, Yang X. Quercetin induces bladder cancer cells apoptosis by activation of AMPK signaling pathway. Am J Cancer Res. 2016;6(2):498\u2013508.","journal-title":"Am J Cancer Res"}],"container-title":["BMC Complementary Medicine and Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12906-026-05279-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12906-026-05279-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12906-026-05279-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T14:52:43Z","timestamp":1774018363000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12906-026-05279-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,13]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5279"],"URL":"https:\/\/doi.org\/10.1186\/s12906-026-05279-5","relation":{},"ISSN":["2662-7671"],"issn-type":[{"value":"2662-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,13]]},"assertion":[{"value":"23 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"105"}}